Aptima HIV-1 Quant Assay
Device
Gen-Probe, Inc.
Total Payments
$48,741
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $48,741 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,741 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Assessment of Markers of Nutritional, Microbial Translocation, Inflammation and Immune Activiation Status, Low-level Viremia and HIV Treatment Outcomes in Resource-limited Settings | Gen-Probe, Inc. | $41,491 | 0 |
| Development of the Hologic HIV Dx Quant assay for use on the Panther System | Gen-Probe, Inc. | $7,250 | 0 |
Top Doctors Receiving Payments for Aptima HIV-1 Quant Assay
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $48,741 | 2 |
Ad
Manufacturing Companies
- Gen-Probe, Inc. $48,741
Product Information
- Type Device
- Total Payments $48,741
- Total Doctors 0
- Transactions 2
About Aptima HIV-1 Quant Assay
Aptima HIV-1 Quant Assay is a device associated with $48,741 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Gen-Probe, Inc..
Payment data is available from 2018 to 2018. In 2018, $48,741 was paid across 2 transactions to 0 doctors.
The most common payment nature for Aptima HIV-1 Quant Assay is "Unspecified" ($48,741, 100.0% of total).
Aptima HIV-1 Quant Assay is associated with 2 research studies, including "Assessment of Markers of Nutritional, Microbial Translocation, Inflammation and Immune Activiation Status, Low-level Viremia and HIV Treatment Outcomes in Resource-limited Settings" ($41,491).